Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06154278 | Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B | PHASE2 | RECRUITING | 10 | — | — | Jul 25, 2024 | Jul 1, 2027 | Sep 11, 2025 | 1 | United States |
Intrahepatic drug concentration at day 0 (peak) and week 32 (trough)
| Arm | Type | Description |
|---|---|---|
| Imdusiran (AB-729) | EXPERIMENTAL | Participants receive subcutaneous injections of 60mg, one injection every 8 weeks for 4 doses. |
| Name | Type | Description |
|---|---|---|
| Imdusiran (AB-729) | DRUG | 60mg subcutaneously, every 8 weeks, for a total of 4 doses |
Inclusion Criteria: 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Male or female, over 18 years of age on the date of screening 4. In good general health as evidenced by medical hist...